S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307

• Status: Withdrawn
• Trial end date: 2010-02-01
• Target enrollment: 0
• Participant gender: Female

Summary

RATIONALE: Gathering information over time from imaging and laboratory tests of women receiving bisphosphonates for breast cancer may help doctors learn more about long-term bone quality and plan the best treatment. Tetracycline hydrochloride and demeclocycline hydrochloride can mark the new growth of the bone, so it may be seen better under a microscope.

PURPOSE: This clinical trial is studying long-term bone quality in women with breast cancer enrolled on clinical trial SWOG-S0307.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Southwest Oncology Group
• Collaborator: National Cancer Institute (NCI)
• Treatments: Clodronic Acid; Demeclocycline; Ibandronic Acid; Tetracycline; Zoledronic Acid

Criteria

DISEASE CHARACTERISTICS:

• Concurrently enrolled on clinical trial SWOG-S0307 and receiving bisphosphonates as adjuvant therapy for primary breast cancer

• No rickets, osteogenesis imperfecta, osteosclerosis, or osteomalacia

• No bone fracture since the age of 21 years unless it was caused by trauma

• Hormone receptor status not specified

PATIENT CHARACTERISTICS:

• Menopausal status not specified

• Weight < 300 lbs

• No hyperparathyroidism

• No serious concurrent or prior anorexia nervosa diagnosed by a physician and causing abnormal menstruation

• No history of hypersensitivity to tetracycline or demeclocycline

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• More than 10 years since prior prednisone at a dose above 5 mg/day for ≥ 3 months

• No prior prednisone before diagnosis of breast cancer

• No prior bisphosphonate therapy

• No concurrent anticonvulsant medications